Goodwin and colleagues [114] have administered Metformin, an oral anti-diabetic drug, to lower insulin levels in women with early breast cancer, and are trying to evaluate the effect of the novel approach on breast cancer outcomes in the later stage of the clinical trial. The gene discussed is INS; the disease is breast cancer.